Clinical Trials on Pulmonary Disease, Chronic Obstructive in Norway

Total 821 results

AstraZeneca

Recruiting

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PROSPERO)

Chronic Obstructive Pulmonary Disease (COPD)

China, Denmark, United States, Australia, Canada, Germany, Netherlands, Poland, Spain, United Kingdom, Korea, Republic of, Philippines, Italy, Argentina, Belgium, Bulgaria, Czechia, Finland, Hungary, India, Japan, Mexico, Norway, Port... and more
St. Olavs Hospital
Norwegian University of Science and Technology

Completed

Calprotectin I Serum as a Diagnostic Marker

Pulmonary Disease, Chronic Obstructive

Norway
Novartis Pharmaceuticals

Completed

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Chronic Obstructive Pulmonary Disease (COPD) With Cachexia

United States, United Kingdom, Netherlands
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, Germany, United Kingdom, China, Philippines, Italy, Chile, Taiwan, Thailand, France, Puerto Rico, Israel, Peru, Colombia, Poland, Brazil, Russian Federation, Romania, Greece
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
AstraZeneca

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

COPD (Chronic Obstructive Pulmonary Disease)

France, Denmark, Italy, Spain, United States, Canada, Argentina, Japan, Colombia, Germany, Peru, Brazil, China, India, Thailand, Austria, Serbia, Malaysia, Philippines, Poland, Taiwan, Greece, Norway, Sweden, Mexico, Romania, Korea, Republic... and more
Norwegian University of Science and Technology
The Research Council of Norway

Completed

Well Being and Rehabilitation in Chronically Ill Patients: Structured Patient Education and Physical Exercise

Heart Failure | Stroke | Chronic Obstructive Pulmonary Disease

Norway
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Belgium, Australia, Israel, Spain, France, United Kingdom, Denmark, Argentina, Germany, New Zealand, South Africa, Korea, Republic of, Poland, Bulgaria, Canada, Chile, Czechia, Netherlands, Romania, Sweden, Mexico
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Genentech, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States, Israel, Australia, Denmark, Korea, Republic of, Spain, Belgium, France, Bulgaria, Poland, United Kingdom, Germany, Canada, Netherlands, Peru, Argentina, Hong Kong, South Africa, New Zealand, Sweden, Czechia, Chile, Ro... and more
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

COPD

United States
Boehringer Ingelheim

Completed

Re-usable Respimat® Soft MistTM Inhaler Study

Pulmonary Disease, Chronic Obstructive

Denmark, Netherlands, Finland, Belgium, Germany, Norway
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
AstraZeneca

Completed

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, France, Italy, Spain, Turkey, United Kingdom, Germany, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Greece, Ireland, Switzerland
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Teva Pharmaceuticals Europe

Completed

Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease (SPRINT)

Chronic Obstructive Pulmonary Disease | Asthma

Croatia, Denmark, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Poland, Spain, United Kingdom, Denmark, Canada, Germany
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Chile, Sweden, Spain, Hungary, Czechia, Norway
Pfizer

Completed

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Costa Rica, Brazil, Chile, Mexico, Argentina
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
The Hospital of Vestfold
Sensocure AS

Not yet recruiting

Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor (DISCO)

Pulmonary Disease, Chronic Obstructive | Neuromuscular Diseases | Hypercapnic Respiratory Failure | Obesity Hypoventilation Syndrome (OHS)

Norway
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Austria, Canada, Germany, Greece, New Zealand, Norway, Slovakia, South Africa, Sweden
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Romania, Italy, Spain, Belgium, Denmark, Estonia, Sweden, Austria, Latvia, United Kingdom, Ukraine, Russian Federation, Greece, Czech Republic, Slovenia, Norway, Lithuania, Slovakia
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
AstraZeneca
Parexel

Completed

Observational Study of Obstructive Lung Disease (NOVELTY) (NOVELTY)

Chronic Obstructive Pulmonary Disease | Asthma | COPD

United States, Canada, Germany, Italy, Spain, United Kingdom, Mexico, Australia, Argentina, France, China, Japan, Brazil, Korea, Republic of, Colombia, Denmark, Netherlands, Norway, Sweden
GlaxoSmithKline

Completed

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

Pulmonary Disease, Chronic Obstructive

United States

Clinical Trials on Pulmonary Disease, Chronic Obstructive in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations